OMOP in Sweden
In 2018 a couple of leaders in Sweden started to explore the world of OMOP. They were the first early adopters. It was AstraZeneca and WHO's Uppsala Monitoring Center. They took initiative to form part of the consortium for the EHDEN initiative funded through the Innovative Medicines Initiative, supported by European Union's Horizon 2020 research and innovation programme and EFPIA. A few organisations have followed them and become data partners with either EHDEN Foundation and/or EMA's DARWIN-EU. For example, the department of Medical Epidemiology and Biostatistics (MEB) at Karolinska Institutet, the department of Biomedical and Clinical Sciences (BKV) at Linkoping University, who have mapped the Swedish Inflammatory Bowel Disease Registry to OMOP, and finally the research project SCIFI-PEARL at Gothenburg University. This last data set has recently, April 2025, also become the first Swedish data partner within EMA's DARWIN-EU network. More organisations are starting to explore the potential of OMOP and the methods and tools from the open-science network OHDSI.
Government assignment to investigate and describe prerequisites, costs, and benefits of making Swedish health registries available according to OMOP CDM to facilitate international collaboration and research.
Mapped Swedish registry data to OMOP CDM via EHDEN and became a data partner to EHDEN Foundation. Also used OMOP CDM in Stockholm CREAtinine Measurements to quantify medication errors and CKD burden.
National linked observational study with regular updates. Data partner to EHDEN Foundation and, since April 2025, to EMA's DARWIN-EU.
Mapped to OMOP through EHDEN and data partner to EHDEN Foundation.
Leader in using Real-World Evidence and federated OMOP-harmonized datasets in pharmacovigilance studies.
Contributes to FLORENCE with expertise in trustworthy and robust AI and privacy-preserving federated learning on OMOP data.
DARWIN EU is established by EMA and the European Medicines Regulatory Network to provide timely and reliable evidence on medicine use, safety, and effectiveness from EU healthcare databases.